KPV

Tripeptide fragment of alpha-MSH studied in anti-inflammatory signaling models. For in-vitro research only.

• Uptake experiments with tritiated peptide and cold competition established transport by PepT1 in intestinal epithelial and immune cell lines, and nanomolar concentrations inhibited NF-kappaB and MAP kinase signalling in those cells. [1]
• In bronchial epithelial cells the peptide entered the nucleus, stabilised IkappaB alpha and blocked nuclear translocation of p65RelA through an interaction at the importin alpha binding site, a route the authors separate from melanocortin receptor activation. [2]
• The related four-residue peptide GKPV inhibited TNF-alpha stimulated NF-kappaB reporter activity both as a soluble peptide and while immobilised on beads, which the authors read as a cell surface receptor based mechanism. [3]
• Two recent cell culture papers report reactive oxygen species as the upstream step, with downstream MAPK and NF-kappaB changes in keratinocytes and PPAR gamma and fatty acid synthase changes in a hepatic cell line. [4] [5]

Compound

KPV

Purity

99.50% (HPLC)

Identity

Confirmed by MS

Appearance

White lyophilate

Presentation

10 mg

Catalog / lot

RV-0025 / RV-24-0025-1

For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or supplement.

Review the laboratory, lot identifier, and reported results in this document. Keep the lot identifier with your research records.